Physical Medicine, Rheumatology and Rehabilitation, Public Health and Community Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
Eur Rev Med Pharmacol Sci. 2022 Jun;26(12):4477-4485. doi: 10.26355/eurrev_202206_29087.
Psychological distress caused by the SARS-CoV-2 outbreak has had deleterious effects on patients with chronic rheumatic disease, as those patients were highly susceptible for COVID-19 infection due to their chronicity, in addition to use of immunosuppressive drugs. Therefore, they underwent to more isolation than other people and develop more stress and depression. This study aimed at evaluating level of depression, anxiety, stress symptoms and physical health status in Egyptian patients with various rheumatic diseases during COVID-19 pandemic.
This is a cross-sectional study conducted in Gharbia Governorate, Egypt. It included 440 diagnosed cases of rheumatic diseases from 1st to the end of March 2021. Depression, Anxiety and Stress Scale-21 (DASS21) and RAPID3/MDHAQ test were used to assess the pandemic's psychological and functional effect on participants.
RAPID3 test results showed that during the COVID-19 outbreak the 40% of patients had a moderate severity functional affection and 20% had high severity. DASS21 depression scoring showed mild to moderate depression (33% and 35%, respectively), while severe depression was detected in only 3.2% of cases. Moderate anxiety was reported in 49% of cases, 29% had severe anxiety while 1% showed extremely severe anxiety. Mild to moderate stress was reported in 17% and 16%, respectively. Female and cases aged more than 45 years had significantly more severe functional affection recorded by RAPID3 test, moderate stress and severe anxiety. On the other hand, severe depression was significantly higher in male and young patients younger than 45 years old.
Rheumatic disease patients have been highly susceptible to functional affection and psychological distress related to COVID-19 pandemic. Planning and implementation of programs to enforce coping strategies for these patients are required.
由于慢性疾病和免疫抑制药物的使用，SARS-CoV-2 爆发导致的心理困扰对慢性风湿性疾病患者产生了有害影响，因此这些患者极易感染 COVID-19。因此，他们比其他人受到更多的隔离，并产生更多的压力和抑郁。本研究旨在评估埃及各种风湿性疾病患者在 COVID-19 大流行期间的抑郁、焦虑、压力症状和身体健康状况。
这是一项在埃及盖尔比亚省进行的横断面研究。它包括 2021 年 1 月至 3 月底的 440 名确诊的风湿性疾病患者。使用抑郁、焦虑和压力量表-21（DASS21）和 RAPID3/MDHAQ 测试评估大流行对参与者的心理和功能影响。
RAPID3 测试结果显示，在 COVID-19 爆发期间，40%的患者功能中度严重受损，20%的患者功能高度严重受损。DASS21 抑郁评分显示轻度至中度抑郁（分别为 33%和 35%），而只有 3.2%的病例出现重度抑郁。中度焦虑见于 49%的病例，重度焦虑见于 29%的病例，1%的病例出现极度严重焦虑。轻度至中度压力分别见于 17%和 16%的病例。女性和年龄超过 45 岁的患者 RAPID3 测试记录的功能损伤、中度压力和严重焦虑更为严重。另一方面，男性和年龄小于 45 岁的年轻患者重度抑郁的发生率明显更高。
风湿性疾病患者极易受到与 COVID-19 大流行相关的功能损伤和心理困扰的影响。需要制定和实施计划，为这些患者实施应对策略。
